Phaseline

Companies › Flare Therapeutics

Flare Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FX-909
PPARG transcription inhibitor (basal- and ligand-activated)
PPARGPhase 1Advanced Urothelial CarcinomaOct 2027
FX-111–Phase 1Metastatic Castration Resistant Prostate CancerFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05929235FX-909Phase 1Advanced Urothelial CarcinomaOncologyOct 2027
NCT07719361FX-111Phase 1Metastatic Castration Resistant Prostate CancerOncologyFeb 2028

Targets

PPARG (1)

Companies with the same targets

Zydus Therapeutics Boryung Pharmaceutical Minoryx Therapeutics Dong Wha Pharmaceutical Inventiva Pharma

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.